Goldman Sachs’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$852M Sell
14,054,518
-4,288,459
-23% -$250M 0.1% 196
2025
Q4
$989M Buy
18,342,977
+757,995
+4% +$36.5M 0.12% 145
2025
Q3
$793M Buy
17,584,982
+5,273,954
+43% +$246M 0.1% 183
2025
Q2
$570M Sell
12,311,028
-934,191
-7% -$45.9M 0.08% 244
2025
Q1
$808M Buy
13,245,219
+941,849
+8% +$54.9M 0.13% 141
2024
Q4
$696M Sell
12,303,370
-406,932
-3% -$22.7M 0.11% 160
2024
Q3
$658M Sell
12,710,302
-3,030,425
-19% -$142M 0.11% 179
2024
Q2
$654M Sell
15,740,727
-230,832
-1% -$10.3M 0.11% 174
2024
Q1
$866M Sell
15,971,559
-387,977
-2% -$19.8M 0.15% 125
2023
Q4
$839M Sell
16,359,536
-984,542
-6% -$51.7M 0.15% 123
2023
Q3
$1.01B Buy
17,344,078
+840,138
+5% +$51.5M 0.21% 82
2023
Q2
$1.06B Sell
16,503,940
-669,878
-4% -$44.9M 0.23% 69
2023
Q1
$1.19B Buy
17,173,818
+1,470,325
+9% +$104M 0.27% 57
2022
Q4
$1.13B Buy
15,703,493
+162,073
+1% +$12.2M 0.28% 51
2022
Q3
$1.1B Buy
15,541,420
+1,184,317
+8% +$85.9M 0.28% 50
2022
Q2
$1.11B Sell
14,357,103
-1,751,823
-11% -$133M 0.28% 52
2022
Q1
$1.18B Buy
16,108,926
+4,114,062
+34% +$276M 0.25% 55
2021
Q4
$748M Sell
11,994,864
-2,270,599
-16% -$133M 0.15% 113
2021
Q3
$844M Buy
14,265,463
+1,574,543
+12% +$104M 0.18% 89
2021
Q2
$848M Sell
12,690,920
-987,076
-7% -$64.4M 0.19% 81
2021
Q1
$863M Buy
13,677,996
+4,085,439
+43% +$254M 0.22% 65
2020
Q4
$595M Buy
9,592,557
+1,000,142
+12% +$61.5M 0.15% 114
2020
Q3
$518M Sell
8,592,415
-7,797,577
-48% -$469M 0.15% 122
2020
Q2
$964M Buy
16,389,992
+923,504
+6% +$55.2M 0.29% 50
2020
Q1
$862M Sell
15,466,488
-1,873,665
-11% -$115M 0.3% 57
2019
Q4
$1.11B Buy
17,340,153
+7,024,051
+68% +$402M 0.28% 58
2019
Q3
$523M Sell
10,316,102
-308,647
-3% -$14.5M 0.15% 117
2019
Q2
$482M Sell
10,624,749
-531,821
-5% -$24.8M 0.14% 135
2019
Q1
$532M Sell
11,156,570
-918,233
-8% -$45.7M 0.16% 107
2018
Q4
$628M Sell
12,074,803
-1,203,327
-9% -$64.7M 0.2% 83
2018
Q3
$824M Buy
13,278,130
+1,520,575
+13% +$90.2M 0.21% 76
2018
Q2
$651M Sell
11,757,555
-2,435,505
-17% -$132M 0.18% 92
2018
Q1
$898M Buy
14,193,060
+3,023,049
+27% +$194M 0.23% 71
2017
Q4
$684M Sell
11,170,011
-1,014,106
-8% -$63.4M 0.16% 106
2017
Q3
$777M Buy
12,184,117
+1,857,623
+18% +$108M 0.19% 75
2017
Q2
$575M Sell
10,326,494
-434,424
-4% -$23.6M 0.15% 111
2017
Q1
$585M Buy
10,760,918
+4,038,096
+60% +$221M 0.16% 105
2016
Q4
$393M Sell
6,722,822
-108,451
-2% -$5.93M 0.11% 163
2016
Q3
$368M Buy
6,831,273
+897,835
+15% +$57.7M 0.11% 163
2016
Q2
$436M Buy
5,933,438
+683,786
+13% +$48.3M 0.14% 113
2016
Q1
$335M Buy
5,249,652
+262,049
+5% +$16.5M 0.11% 173
2015
Q4
$343M Sell
4,987,603
-893,871
-15% -$59.1M 0.11% 182
2015
Q3
$348M Sell
5,881,474
-378,382
-6% -$24M 0.12% 156
2015
Q2
$417M Sell
6,259,856
-356,317
-5% -$23.5M 0.13% 146
2015
Q1
$427M Sell
6,616,173
-1,430,320
-18% -$89.5M 0.14% 142
2014
Q4
$475M Buy
8,046,493
+505,143
+7% +$28.5M 0.15% 119
2014
Q3
$386M Buy
7,541,350
+720,694
+11% +$36M 0.12% 143
2014
Q2
$331M Buy
6,820,656
+123,383
+2% +$6.08M 0.1% 191
2014
Q1
$348M Buy
6,697,273
+709,608
+12% +$37.8M 0.11% 172
2013
Q4
$318M Sell
5,987,665
-48,610
-0.8% -$2.48M 0.1% 198
2013
Q3
$279M Sell
6,036,275
-1,731,194
-22% -$76M 0.1% 193
2013
Q2
$347M Buy
+7,767,469
New +$337M 0.13% 139

Other funds holding BMY

Goldman Sachs's BMY Position: Q1 2026 in Review

Goldman Sachs reduced its Bristol-Myers Squibb (BMY) stake by 23% in Q1 2026, selling an estimated $250M and leaving 14,054,518 shares worth $852M. The position accounts for 0.1% of the portfolio, ranked #196.

Goldman Sachs first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.19B in Q1 2023. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Goldman Sachs held 14,054,518 shares of Bristol-Myers Squibb worth $852M as of Q1 2026.
  • Goldman Sachs sold 4,288,459 Bristol-Myers Squibb shares in Q1 2026, an estimated $250M.
  • Bristol-Myers Squibb made up 0.1% of Goldman Sachs's portfolio in Q1 2026, its #196 holding.
  • Goldman Sachs first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Bristol-Myers Squibb position peaked at $1.19B in Q1 2023.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.